Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells

Phase 1

Completed

Conditions: Lymphoma
Leukemia

Interventions: Genetic: T-Cell Infusion
Procedure: Cord Blood Infusion

First Posted Date: 2011-05-30

Last Posted Date: 2017-08-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT01362452

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Phase 2

Active, not recruiting

Conditions: CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma
Cutaneous Lymphomas
Hematologic Disorder
Lymphoma, Primary Cutaneous Anaplastic Large Cell
Lymphomatoid Papulosis
Mycosis Fungoides
Skin Lymphoma
Lymphoma

Interventions: Drug: SGN-35

First Posted Date: 2011-05-12

Last Posted Date: 2025-02-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 79

Registration Number: NCT01352520

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Open-Label Study of TPI 287 for Patients With Metastatic Melanoma

Phase 1

Withdrawn

Conditions: Metastatic Melanoma

Interventions: Drug: TPI 287

First Posted Date: 2011-04-25

Last Posted Date: 2013-04-05

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01340729

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: Pazopanib
Drug: Vorinostat

First Posted Date: 2011-04-21

Last Posted Date: 2017-06-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 152

Registration Number: NCT01339871

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Phase 1

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: Liposomal Doxorubicin
Drug: Seliciclib

First Posted Date: 2011-04-12

Last Posted Date: 2012-06-26

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01333423

Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer

Phase 2

Active, not recruiting

Conditions: Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage IA Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Anatomic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8

Interventions: Procedure: Biopsy
Procedure: Conventional Surgery
Other: Genetic Testing

First Posted Date: 2011-04-12

Last Posted Date: 2025-04-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1100

Registration Number: NCT01334021

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

TPI 287 in Breast Cancer Metastatic to the Brain

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: TPI 287
Drug: Dexamethasone
Drug: Benadryl
Drug: Ranitidine

First Posted Date: 2011-04-11

Last Posted Date: 2018-09-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT01332630

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Single Agent Armodafinil for Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer

Phase 1

Completed

Conditions: Head And Neck Cancer
Fatigue

Interventions: Other: Placebo
Drug: Armodafinil
Behavioral: Questionnaires

First Posted Date: 2011-04-07

Last Posted Date: 2024-02-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 26

Registration Number: NCT01330446

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Lyndon B. Johnson General Hospital, Houston, Texas, United States

Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Ofatumumab
Drug: Ifosfamide
Drug: Etoposide
Drug: Mesna
Drug: G-CSF
Procedure: Stem Cell Collection

First Posted Date: 2011-04-06

Last Posted Date: 2020-07-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT01329900

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

Phase 2

Completed

Conditions: Infection
Bacteremia

Interventions: Drug: Telavancin

First Posted Date: 2011-03-24

Last Posted Date: 2019-12-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT01321879

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy